Beam Therapeutics Inc. (BEAM) has a consensus analyst rating of Buy, based on 27 analysts covering the stock. Of those, 18 recommend buying, 8 recommend holding, and 1 recommend selling.
The analyst consensus price target for BEAM is $40.86, representing a +34.9% upside from the current price of $30.3. Price targets range from a low of $26.00 to a high of $74.00.
